Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FLGC Flora Growth	$21.26 +6.7%	$23.61	$15.15 ▼ $82.29	$12.28M	1.97	17,871 shs	3,587 shs
GOVX GeoVax Labs	$0.77 +2.7%	$0.76	$0.43 ▼ $8.28	$12.20M	3.27	1.01 million shs	867,261 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
QLGN Qualigen Therapeutics	$1.86 +1.6%	$2.83	$1.61 ▼ $10.50	$3.15M	-0.17	97,564 shs	15,203 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FLGC Flora Growth	+6.72%	-10.04%	-10.65%	-22.35%	-42.01%
GOVX GeoVax Labs	+2.69%	+1.40%	-9.51%	-23.76%	-90.78%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
QLGN Qualigen Therapeutics	+0.27%	-2.11%	-36.95%	-50.66%	-81.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FLGC Flora Growth	3.3034 of 5 stars	3.5	5.0	0.0	0.0	3.3	0.8	0.6
GOVX GeoVax Labs	1.849 of 5 stars	3.5	2.0	0.0	0.0	2.0	0.0	0.6
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
QLGN Qualigen Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FLGC Flora Growth	3.00	Buy	$93.00	337.46% Upside
GOVX GeoVax Labs	3.00	Buy	$8.50	1,003.90% Upside
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
QLGN Qualigen Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest QLGN, FLGC, GOVX, and PHXM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
8/5/2025	FLGC Flora Growth	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$30.00
7/29/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
7/17/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/16/2025	GOVX GeoVax Labs	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FLGC Flora Growth	$59.51M	0.21	N/A	N/A	$6.95 per share	3.06
GOVX GeoVax Labs	$3.95M	3.11	N/A	N/A	$0.18 per share	4.28
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
QLGN Qualigen Therapeutics	$4.98M	0.63	N/A	N/A	($2.62) per share	-0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FLGC Flora Growth	-$15.91M	-$34.38	N/A	N/A	N/A	-24.86%	-261.57%	-48.06%	N/A
GOVX GeoVax Labs	-$24.99M	-$2.01	N/A	N/A	N/A	-403.88%	-408.80%	-279.89%	11/11/2025 (Estimated)
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QLGN Qualigen Therapeutics	-$6.26M	N/A	0.00	∞	N/A	N/A	N/A	-202.16%	N/A

Latest QLGN, FLGC, GOVX, and PHXM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	QLGN Qualigen Therapeutics	N/A	-$1.00	N/A	-$1.00	N/A	N/A
8/1/2025	Q2 2025	FLGC Flora Growth	-$0.06	-$0.11	-$0.05	-$0.11	$11.77 million	$14.80 million
7/28/2025	Q2 2025	GOVX GeoVax Labs	-$0.41	-$0.35	+$0.06	-$0.35	$0.37 million	$0.85 million
7/21/2025	Q1 2025	QLGN Qualigen Therapeutics	N/A	-$1.82	N/A	-$1.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FLGC Flora Growth	N/A	N/A	N/A	N/A	N/A
GOVX GeoVax Labs	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
QLGN Qualigen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FLGC Flora Growth	0.50	0.96	0.61
GOVX GeoVax Labs	N/A	2.03	2.03
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
QLGN Qualigen Therapeutics	N/A	0.71	1.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FLGC Flora Growth	36.01%
GOVX GeoVax Labs	6.09%
PHXM PHAXIAM Therapeutics	0.40%
QLGN Qualigen Therapeutics	3.18%

Insider Ownership

Company	Insider Ownership
FLGC Flora Growth	12.56%
GOVX GeoVax Labs	1.20%
PHXM PHAXIAM Therapeutics	1.94%
QLGN Qualigen Therapeutics	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FLGC Flora Growth	280	580,000	506,000	Not Optionable
GOVX GeoVax Labs	10	15.93 million	15.73 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
QLGN Qualigen Therapeutics	50	1.70 million	1.66 million	Not Optionable

QLGN, FLGC, GOVX, and PHXM Headlines

Recent News About These Companies

Qualigen Therapeutics (NASDAQ:QLGN) Shares Up 1.6% - What's Next?

August 23 at 3:55 AM | americanbankingnews.com

Qualigen Therapeutics, Inc.: Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status

July 30, 2025 | finanznachrichten.de

Qualigen Therapeutics Announces $4.5M Private Placement

July 29, 2025 | msn.com

Qualigen Therapeutics provides update on Nasdaq listing status

July 28, 2025 | msn.com

Qualigen Therapeutics Secures Nasdaq Compliance Extension

July 28, 2025 | msn.com

Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status

July 28, 2025 | finance.yahoo.com

Qualigen Therapeutics, Inc. Secures $4.5 Million Through Series A-3 Preferred Stock Private Placement

July 28, 2025 | quiverquant.comQ

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

July 28, 2025 | globenewswire.com

Qualigen Granted New Patents Covering 25 Countries

July 16, 2025 | manilatimes.netM

Qualigen Therapeutics shares surge after patent approvals in 25 countries

July 16, 2025 | msn.com

Qualigen Therapeutics, Inc. (QLGN) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Qualigen Therapeutics faces potential Nasdaq delisting

May 21, 2025 | uk.investing.com

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...

May 19, 2025 | gurufocus.com

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...

May 19, 2025 | gurufocus.com

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to ...

May 19, 2025 | gurufocus.com

Qualigen Therapeutics Faces Nasdaq Delisting Notification

May 19, 2025 | tipranks.com

Qualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing Deficiency

May 19, 2025 | quiverquant.comQ

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

May 19, 2025 | globenewswire.com

Marizyme, Inc. (MRZM) Latest Press Releases & Corporate News - Yahoo Finance

May 10, 2025 | finance.yahoo.com

Qualigen Therapeutics Faces Nasdaq Delisting Threat

May 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN, FLGC, GOVX, and PHXM Company Descriptions

Flora Growth NASDAQ:FLGC

$21.26 +1.34 (+6.72%)

Closing price 08/22/2025 03:58 PM Eastern

Extended Trading

$21.89 +0.63 (+2.97%)

As of 08/22/2025 06:35 PM Eastern

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

GeoVax Labs NASDAQ:GOVX

$0.77 +0.02 (+2.69%)

As of 08/22/2025 04:00 PM Eastern

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/22/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Qualigen Therapeutics NASDAQ:QLGN

$1.86 +0.03 (+1.64%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$1.84 -0.02 (-1.02%)

As of 08/22/2025 07:31 PM Eastern

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time